Tags:BuildingChemicalPhysical
Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the existing 20 natural amino acids, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. Ambrx is based in the USA in La Jolla, CA.
Total raised: $297M

Investors 3

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
09.11.2020-$200M--
05.08.2016-$45M--
06.07.2006-$52M--

Mentions in press and media 229

DateTitleDescriptionCategoryAuthorSource
07.01.2021Ambrx Appo... SAN DIEGO, Jan. 7, 2021 /PRN...--prnewswire...
24.11.2020Af­ter 5 q...The first time San Diego biote...FinancingJason Mastendpts.com...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
23.11.2020Ambrx has ...---connect.or...
Show more